Doximity earnings spark fresh focus on AI and valuation

Doximity (DOCS) has jumped back onto investors' radar after its early August first quarter report, which combined revenue growth, a high adjusted EBITDA margin and a higher full year revenue outlook.

The earnings release also highlighted rapid take up of Doximity's clinical AI tools, independent recognition of their safety profile and early monetization of new AI features, all against a backdrop of mixed analyst views on the stock.

Doximity's Q1 update has been a clear turning point for sentiment, with the stock's 1 day share price return of 32.62% and 7 day share price return of 26.50% standing in contrast to a year to date share price decline of 36.71% and a 1 year total shareholder return decline of 55.68%. The 3 year total shareholder return of 18.05% suggests longer term holders have still seen positive gains.

If the renewed focus on clinical AI has caught your attention, this could be a good moment to see what else is moving in healthcare technology with 43 healthcare AI stocks

After a one-day jump of more than 30%, Doximity now sits closer to many fair value estimates but still below some analyst targets. Is this Q1 reset already in the price, or is waiting for a better entry more sensible?

Most Popular Narrative: 18.7% Undervalued

Based on the most followed narrative, Doximity's fair value of $33.70 sits above the recent $27.40 close, which puts a spotlight on what believers in the story are seeing.

What I like about Doximity is that there really is a very high viewership / user base of active practicing Physicians in the US and that is not invaluable and definitely could be monetized perhaps more efficiently. I also think that Doximity offers a lot of interesting tools for Physicians a lot of which are free and really marketed towards, I think, Physicians who are more in private practice. It’s a little bit unclear how much value that provides given that most Physicians and practitioners these days are employed and not in private practice.

According to Dc12, this valuation leans heavily on strong profit margins, a premium earnings multiple and expectations that Doximity keeps converting physician engagement into higher monetization.

Result: Fair Value of $33.70 (UNDERVALUED)

However, Doximity still faces real tests, including heavier competition in clinical AI tools and uncertainty about how much physician engagement ultimately converts into revenue.

Next Steps

After all this, are you leaning bullish or cautious on Doximity? Take a closer look at both sides of the story and move quickly to shape your own view with 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond Doximity?

If Doximity has sharpened your interest, do not stop here. Use the Simply Wall Street Screener to quickly surface fresh stock ideas that fit your style.

• Target potential mispricing by scanning companies that combine quality fundamentals with attractive valuations through the 52 high quality undervalued stocks.
• Prioritize resilience by checking companies that show sturdy financial positions using the solid balance sheet and fundamentals stocks screener (48 results).
• Spot under-the-radar opportunities by reviewing the screener containing 21 high quality undiscovered gems before other investors catch on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.